WINNIPEG, MB, June 20,
2022 /CNW/ - (June 20,
2022) Medicure Inc. ("Medicure" or the
"Company") (TSXV: MPH) (OTC: MCUJF), a company focused on
the development and commercialization of pharmaceuticals and
healthcare products for patients and prescribers in the United States market, is pleased to
announce that the following individuals were elected as directors
at its Annual General Meeting of shareholders held on June 16, 2022: Dr. Albert Friesen, Gerald
McDole, Brent Fawkes, Dr.
Arnold Naimark, Peter Quick and James
Kinley. In addition, the shareholders re-appointed
Ernst & Young LLP, Chartered Accountants, as auditor of the
Company.
On behalf of the Board of Directors and management, Dr.
Albert D. Friesen, CEO and Chair of
the Board of Directors, stated, "We want to thank Manon Harvey for her tenure as a director and
are pleased to welcome James Kinley
as the newest addition to the Board of Directors."
About Medicure Inc.
Medicure is a pharmaceutical
company focused on the development and commercialization of
therapies for the U.S. cardiovascular market. The present focus of
the Company is the marketing and distribution of
AGGRASTAT® (tirofiban hydrochloride) injection and
ZYPITAMAG® (pitavastatin) tablets in the United States, where they are sold through
the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also
operates Marley Drug, Inc. ("Marley Drug"), a pharmacy located in
North Carolina that offers an
Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug® is
committed to improving the health status of its patients and the
communities they serve while reducing overall health care costs for
employers and other health care consumers. For more information
visit www.marleydrug.com. To learn more about The Extended Supply
Generic Drug Program call 800.286.6781 or email
info@marleydrug.com. For more information on Medicure please
visit www.medicure.com. For additional information about
AGGRASTAT®, refer to the full Prescribing Information.
For additional information about ZYPITAMAG®, refer to
the full Prescribing Information.
To be added to Medicure's e-mail list, please
visit:
http://medicure.mediaroom.com/alerts
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward Looking Information: Statements contained in this
press release that are not statements of historical fact,
including, without limitation, statements containing the words
"believes", "may", "plans", "will", "estimates", "continues",
"anticipates", "intends", "expects" and similar expressions, may
constitute "forward-looking information" within the meaning of
applicable Canadian and U.S. federal securities laws (such
forward-looking information and forward-looking statements are
hereinafter collectively referred to as "forward-looking
statements"). Forward-looking statements, include estimates,
analysis and opinions of management of the Company made in light of
its experience and its perception of trends, current conditions and
expected developments, as well as other factors which the Company
believes to be relevant and reasonable in the circumstances.
Inherent in forward-looking statements are known and unknown risks,
uncertainties and other factors beyond the Company's ability to
predict or control that may cause the actual results, events or
developments to be materially different from any future results,
events or developments expressed or implied by such forward-looking
statements, and as such, readers are cautioned not to place undue
reliance on forward-looking statements. Such risk factors include,
among others, the Company's future product revenues, expected
results, including future revenue from P5P, the likelihood of
receiving a priority review voucher from the United State Food and
Drug Administration, expected future growth in revenues, stage of
development, additional capital requirements, risks associated with
the completion and timing of clinical trials and obtaining
regulatory approval to market the Company's products, the ability
to protect its intellectual property, dependence upon collaborative
partners, changes in government regulation or regulatory approval
processes, and rapid technological change in the industry. Such
statements are based on a number of assumptions which may prove to
be incorrect, including, but not limited to, assumptions about:
general business and economic conditions; the impact of changes in
Canadian-US dollar and other foreign exchange rates on the
Company's revenues, costs and results; the timing of the receipt of
regulatory and governmental approvals for the Company's research
and development projects; the availability of financing for the
Company's commercial operations and/or research and development
projects, or the availability of financing on reasonable terms;
results of current and future clinical trials; the uncertainties
associated with the acceptance and demand for new products and
market competition. The foregoing list of important factors and
assumptions is not exhaustive. The Company undertakes no obligation
to update publicly or otherwise revise any forward-looking
statements or the foregoing list of factors, other than as may be
required by applicable legislation. Additional discussion regarding
the risks and uncertainties relating to the Company and its
business can be found in the Company's other filings with the
applicable Canadian securities regulatory authorities or the US
Securities and Exchange Commission, and in the "Risk Factors"
section of its Form 20F for the year ended December 31, 2021.
AGGRASTAT® (tirofiban hydrochloride) injection and
ZYPITAMAG® (pitavastatin) tablets are registered
trademarks of Medicure International Inc. Marley
Drug® is a registered trademark of Medicure Pharma
Inc.
View original
content:https://www.prnewswire.com/news-releases/medicure-announces-results-of-2022-agm-301571342.html
SOURCE Medicure Inc.
